Biopharma | Ophthalmology Innovation Source

Kala Therapeutics

By penetrating the mucosal barrier in the eye, Kala’s Mucosal Penetrating Products (MPPs) “enhances pharmacokinetics” and can be used to treat both anterior and posterior segment disorders. Top-line results from a Phase 3 clinical trial of KPI-121 (loteprednol) achieved all primary efficacy endpoints in the treatment of inflammation and pain post-cataract surgery. A phase 2/3…

Envisia Therapeutics

ENV515 is a proprietary, fully biodegradable PRINT (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular pressure (IOP) reduction over as many as 6 months. In hypertensive beagles, a “rapid drop” in pressure was maintained over 8 months, Yerxa said, accounting for a 32% reduction in…

Spotlight on Pressure Reduction – Market Overview

Participant: Kuldev Singh, MD, MPH Dr. Kuldev Singh is Professor of Ophthalmology and Director of the Glaucoma Service at the Stanford University School of Medicine. View Full Profile

Jade Therapeutics

Jade’s proprietary, cross-linked, bioerodable hydrogel technology can be used alone as an ocular lubricant, or as a sustained-release vehicle for either anterior or posterior segments. The thiolated carboxymethyl HA (CMHA-S) is “an improved version of the hyaluronic acid (HA) products on the market today for dry eye,” Klausner said. The technology can be produced as…

Eleven Biotherapeutics

Presenter: Abbie C. Celniker, PhD Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals. View Full Profile

Masters of the Universe

Moderator: Jim Mazzo Jim Mazzo is the Executive Chairman and CEO for AcuFocus. AcuFocus specializes in presbyopia correction and is known for its revolutionary KAMRA inlay which was recently FDA approved. View Full Profile Panelists: Jeff George Jeff was appointed to lead Alcon in May 2014. As the global leader in eye care, Alcon provides…

Plenary Talk: Valeant’s Approach to Innovation

Valeant Pharmaceuticals is undergoing increased scrutiny. A year ago, J. Michael Pearson, then president and CEO, laid out the company’s vision for developing new tools in ophthalmology. Presenter: J. Michael Pearson Mr. Pearson has been the CEO and serving on the Board since September 2010 and the Chairman of the Board since March 2011. View…

Cross-linking platform denied FDA approval—for now

UPDATE 4/19/16: Avedro Finally Secures FDA Approval Read Full Story Click Here In late February, a joint panel of the Food and Drug Administration voted to recommend Avedro’s corneal cross-linking platform for regulatory approval. The combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking platform may be approved for the treatment of…

Blumenkranz Shares His Success, Failures And New Opportunities For Ophthalmic Innovators

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 029″] Mark Blumenkranz, MD, has had a hand in starting many exciting biotech, medtech and digital health companies. Hear how his innovative process begins and what he’s doing to help foster new ideas in ophthalmology. Podcast Guest Mark S. Blumenkranz, MD Mark S. Blumenkranz, MD, MMS, is HJ Smead Professor in…

DigiSight Puts Eye Care in Patients’ Hands

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 025″] DigiSight President and CEO Doug Foster explains how mobile technologies like his company’s SightBook app can help save patient vision and help the pharmaceutical industry develop new ophthalmology drugs. Podcast Guest Doug Foster Doug Foster is CEO of DigiSight Technologies. He has over 15 years experience identifying and developing technologies…

Visual Disorders In Space And How Ophthalmology Can Help

View PDF Presentation Presenter: Dorit B. Donoviel, PhD Dr. Donoviel oversees the diverse portfolio of science and technology research and development projects at NSBRI that address the challenges faced by humans in space. She leads the NSBRI Industry Forum and the SMARTCAP seed award program for commercialization of biomedical technologies co-developed for both space and…

Alimera CEO Myers Shares Lessons From Iluvien FDA Approval

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 018″] The FDA turned away Alimera Sciences’ bid to market Iluvien as a treatment for diabetic macular edema three times before finally giving the green light. President & CEO Dan Myers shares what kept his confidence up during this lengthy review and how Alimera Sciences is positioning Iluvien in the DME…